Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. How common it is

Topic: Risk, prevention and care in population studies

This paper examines eight published reviews that each pooled results from several related clinical trials to evaluate treatment efficacy. The authors found that these reviews lacked consistent assessments of treatment effect homogeneity before combining the results. To address this, the study discusses a random effects approach for combining evidence from multiple experiments and suggests a simple noniterative procedure to characterize the distribution of treatment effects.

Key findings

Why it matters

Discusses meta-analysis in clinical trials.

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 0 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 49 of the 95 points it could be judged on, which is 52 of 100. Total 52 of 100.49 of the 95 points we could judge = 52 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 49 of the 95 points we could judge it on, which is 52 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Controlled Clinical Trials)
Journal's citation record 1 / 4 Controlled Clinical Trials: journal h-index 126 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1986 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 39,421 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 938.6 citations a year over 42 year(s) since 1986
Impact for its field and year 5 / 6 Cited 23.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 4 / 4 Cited 5,350 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Nan M. Laird: h-index 98 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 3802833)
Free to read 0 / 2 Behind a paywall — scores zero
Points 49 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 95 points we could judge it on is 52 out of 100.
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

DerSimonian, R., & Laird, N. M. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials. https://doi.org/10.1016/0197-2456(86)90046-2

Vancouver

DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986. doi:10.1016/0197-2456(86)90046-2. PMID: 3802833.

BibTeX

@article{dersimonian1986-3802833,
  author  = {DerSimonian, Rebecca and Laird, Nan M.},
  title   = {{Meta-analysis in clinical trials}},
  journal = {Controlled Clinical Trials},
  year    = {1986},
  doi     = {10.1016/0197-2456(86)90046-2},
  pmid    = {3802833},
  url     = {https://doi.org/10.1016/0197-2456(86)90046-2}
}

Related studies in How common it is

Similar studies

More on How common it is

See all studies in How common it is →